Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Epigenetics of hematopoiesis and hematological malignancies.

Hu D, Shilatifard A.

Genes Dev. 2016 Sep 15;30(18):2021-2041. Review.

2.

The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis.

Ghazzaui N, Saintamand A, Issaoui H, Vincent-Fabert C, Denizot Y.

Oncotarget. 2017 Jan 24;8(4):7059-7067. doi: 10.18632/oncotarget.12535. Review.

3.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.

4.

PIAS1 Promotes Lymphomagenesis through MYC Upregulation.

Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP.

Cell Rep. 2016 Jun 7;15(10):2266-78. doi: 10.1016/j.celrep.2016.05.015. Epub 2016 May 26.

5.

Efficient role of IgH 3' regulatory region deficient B-cells in the development of oil granulomas.

Ghazzaui N, Saintamand A, Issaoui H, Saad F, Denizot Y.

Oncotarget. 2016 Jun 21;7(25):38741-38749. doi: 10.18632/oncotarget.9588.

6.

Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.

Edwards SK, Han Y, Liu Y, Kreider BZ, Liu Y, Grewal S, Desai A, Baron J, Moore CR, Luo C, Xie P.

Leuk Res. 2016 Feb;41:85-95. doi: 10.1016/j.leukres.2015.12.005. Epub 2015 Dec 19.

7.

Pre-germinal center origin for mature mouse B cell lymphomas: a major discrepancy with human mature lymphomas.

Saintamand A, Garot A, Saad F, Moulinas R, Denizot Y.

Cell Cycle. 2015;14(22):3656-8. doi: 10.1080/15384101.2015.1093708. No abstract available.

8.

KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice.

Sin SH, Kim Y, Eason A, Dittmer DP.

PLoS Pathog. 2015 Sep 1;11(9):e1005135. doi: 10.1371/journal.ppat.1005135. eCollection 2015 Sep.

9.

Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms.

Moore CR, Edwards SK, Xie P.

J Cancer Sci Ther. 2015 Feb;7(2):67-74.

10.

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.

Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S.

Exp Hematol Oncol. 2015 Mar 27;4:9. doi: 10.1186/s40164-015-0005-2. eCollection 2015.

11.

Targeting the oncogene B lymphoma deregulator IgH 3' regulatory region does not impede the in vivo inflammatory response in mice.

Saad F, Saintamand A, Rouaud P, Denizot Y.

Oncoscience. 2014 Sep 19;1(9):591-8. eCollection 2014.

12.

Enhancer alterations in cancer: a source for a cell identity crisis.

Kron KJ, Bailey SD, Lupien M.

Genome Med. 2014 Sep 23;6(9):77. doi: 10.1186/s13073-014-0077-3. eCollection 2014.

13.

Murine models of acute leukemia: important tools in current pediatric leukemia research.

Jacoby E, Chien CD, Fry TJ.

Front Oncol. 2014 May 7;4:95. doi: 10.3389/fonc.2014.00095. eCollection 2014. Review.

14.

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S.

Immunol Res. 2014 Aug;59(1-3):188-202. doi: 10.1007/s12026-014-8528-x. Review.

15.

A new model of LMP1-MYC interaction in B cell lymphoma.

Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA.

Leuk Lymphoma. 2014 Dec;55(12):2917-23. doi: 10.3109/10428194.2014.900762. Epub 2014 Apr 23.

16.

Absence of manganese superoxide dismutase delays p53-induced tumor formation.

Case AJ, Domann FE.

Redox Biol. 2014 Jan 13;2:220-3. doi: 10.1016/j.redox.2014.01.001. eCollection 2014.

17.

Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.

Spender LC, Inman GJ.

Cancer Manag Res. 2014 Jan 9;6:27-38. doi: 10.2147/CMAR.S37745. Review.

18.

Non-invasive bioluminescence imaging to monitor the immunological control of a plasmablastic lymphoma-like B cell neoplasia after hematopoietic cell transplantation.

Chopra M, Kraus S, Schwinn S, Ritz M, Mattenheimer K, Mottok A, Rosenwald A, Einsele H, Beilhack A.

PLoS One. 2013 Dec 12;8(12):e81320. doi: 10.1371/journal.pone.0081320. eCollection 2013.

19.

(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.

Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S.

Blood Cancer J. 2013 Nov 29;3:e165. doi: 10.1038/bcj.2013.61.

20.

Homeostatic defects in B cells deficient in the E3 ubiquitin ligase ARF-BP1 are restored by enhanced expression of MYC.

Qi CF, Zhang R, Sun J, Li Z, Shin DM, Wang H, Kovalchuk AL, Sakai T, Xiong H, Kon N, Gu W, Morse HC 3rd.

Leuk Res. 2013 Dec;37(12):1680-9. doi: 10.1016/j.leukres.2013.09.009. Epub 2013 Sep 20.

Supplemental Content

Support Center